INO is up +13.33% during Friday’s regular session, trading near $1.02 versus Thursday’s close of $0.90. The move is primarily a continuation of Thursday’s post-earnings, analyst-upgrade momentum rather than a fresh company-specific headline.

The central question is whether Xencor, Inc. ( XNCR ) can reach a $30 stock price target , roughly 30% above recent trading near $23. The strongest bullish factor is operational momentum: second-quarter results beat expectations by a wide margin, and several clinical catalysts are approaching.

Xencor’s XmAb protein engineering platform positions the company for potential advances in bispecific antibody therapies targeting cancer and autoimmune diseases, with multiple programs in clinical development. Upcoming clinical data readouts and regulatory milestones for candidates such as XmAb942 in inflammatory bowel disease (IBD) represent key near-term catalysts that could influence investor sentiment.

XNCR advanced approximately 50.2% in the 30-day period, rising from a $14.98 close on July 15, 2026, to roughly $22.50 in mid-August. The move accelerated after Xencor announced that Phase 1 expansion-cohort data for XmAb819 in advanced clear cell renal cell carcinoma was selected for an oral presentation at ESMO 2026.

INO is trading up +2.42% at $0.9219 during regular market hours as of roughly 10:09 a.m. ET, compared with Thursday’s close of $0.9001. The advance extends Thursday’s +16.90% jump after Jefferies upgraded Inovio to Buy from Hold and raised its price target to $3.00 from $1.80 on positive FDA review progress for INO-3107.

HeartFlow shares are up +25.64% in regular trading Friday at $38.96, versus the prior close of $31.01. The move extends an after-hours surge following Q2 results: revenue rose +48% year-over-year to $64.1 million, beating forecasts, and adjusted loss per share of -$0.07 was much narrower than expected.

NU is trading up +13.07% at $15.75 in early regular trading, extending an after-hours/premarket surge after Q2 results were released following Thursday's close. Primary catalyst: Q2 2026 net income reached a record $1.06 billion, its first billion-dollar quarter, up +49% year over year and above consensus; revenue rose +39% to $5.88 billion.

ENHA is down -18.00% during regular trading on Aug. 14, sliding to about $2.05 from a prior close of $2.50. The selloff follows Q2 results released after the Aug. 13 close, with revenue of $17.71M missing expectations by $6.89M and GAAP EPS of -$0.53.

MRLN fell -16.74% in Friday's regular session to $3.68, down from Wednesday's close of $4.42. The drop follows Q2 2026 results reported after Wednesday's close: revenue of about $2.2 million missed the roughly $3.8 million consensus, and an adjusted loss of $1.11 per share was far wider than the $0.28 expected.

KinderCare Learning (KLC) is down -26.50% to $3.55 in early regular trading, extending losses that began after-hours Wednesday. The selloff follows Q2 adjusted EPS of $0.08, missing the $0.10 consensus, with revenue down -0.4% YoY to $697.5M.

YSS is down -11.03% to $10.24 in early regular trading on Aug. 14, versus a prior close of $11.51. The decline extends a post-earnings selloff that began after the Aug. 13 close and steepened in premarket trading, where shares fell roughly -15% at the lows.

ARS Pharmaceuticals (SPRY) is trading down -10.25% at $5.48 in early regular trading, versus a $6.10 close on Aug 13. The move follows Q2 results released after the prior close: EPS came in at -$0.63, missing the -$0.50 consensus, while revenue of $33.7M beat the $31.5M estimate.

Modular Medical (MODD) closed at $1.87 on August 13, 2026, down approximately 57% from the $4.31 closing price recorded 30 calendar days earlier on July 14, 2026. The decline has pushed the stock toward the lower end of its 52-week range of $1.74–$30.00 and well below its 50-day moving average near $3.64.

Nuwellis shares closed at $1.30 on August 13, 2026, down from $3.12 on July 15, 2026, a decline of approximately 58% over the last 30 days. The selloff was driven primarily by dilutive capital-raising activity, including a registered direct offering priced at $2.59 per share on July 31, 2026, and warrant exercise proceeds.

SNWV fell approximately 60% over the last 30 days, from a closing price of $11.96 on July 14, 2026, to $4.77 on August 13, 2026. Second-quarter 2026 revenue of $9.7 million declined 3% year over year and missed consensus estimates near $11.5 million, while the company swung to a net loss of $0.7 million.

NIVF shares fell roughly 59.9% over the 30 days through the August 13, 2026 close, declining from $1.37 to about $0.55. The move extends a deeper downtrend, with the stock down approximately 79.6% over the trailing three months.

Tapestry, Inc. (TPR) reported fiscal 2026 fourth-quarter net sales of $1.88 billion, up 9% year over year, for the period ended June 27, 2026. Adjusted earnings per share (EPS) rose 27% to $1.32, exceeding the consensus estimate of $1.28.

Credicorp Ltd. (NYSE: BAP) reported 2Q26 net profit attributable to shareholders of S/1.98 billion, up 8.8% year over year but down 3.9% from 1Q26. Return on equity (ROE), a measure of profitability, reached 20.3%, down from 21.1% in the prior quarter but above the company's full-year guidance of around 19.5%.

Revenue: JD.com reported second-quarter 2026 net revenues of RMB346.4 billion (US$51.1 billion), down 2.9% year over year but above the consensus estimate of about RMB342.7 billion. Earnings beat: Non-GAAP diluted earnings per American depositary share (ADS) reached RMB6.29 (US$0.93), topping the analyst estimate of RMB5.63.

Nu Holdings reported second-quarter 2026 net income of $1.1 billion, its first quarter above $1 billion, up 49% year over year on a foreign-exchange-neutral (FXN) basis. Gross revenue reached nearly $5.9 billion, up 39% year over year on an FXN basis, while reported revenue of $5.88 billion came in above the roughly $5.39 billion consensus estimate.